The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
|Articles|October 1, 2013
HDMA leadership remains with David Neu of AmerisourceBergen
Mark Walchirk of McKesson joins executive board
Advertisement
At its annual board and membership meeting, the Healthcare Distribution Management Assn. announced the reelection of David Neu, president of AmerisourceBergen Drug Corp., as its chairman, and Ted Scherr, CEO of Dakota Drug, as vice chairman.
Mark Walchirk, president of McKesson US Pharmaceutical, was elected to replace Paul Julien, also of McKesson, as board member and member of the executive committee of HDMA.
Other executive committee members are: Ken Couch, president of Smith Drug Co., Michael Kaufmann, CEO of the Pharmaceutical Segment of Cardinal Health, David Moody, CEO of Mutual Wholesale Drug Co., Dale Smith, chairman of H.D. Smith, and John Gray, president of HDMA.
Mary Tim Smith, CFO of R&S Northeast LLC, was elected as a board member to replace Greg Duche, CEO of R&S Northeast.
Advertisement
Related to this article
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Q&A: Inside the NDC-12 Transition
3
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
4
How Rebate Timing Distorts a Pharmacy's 340B Books
5